Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States)
Tóm tắt
Objective: To examine whether exposures to anti-inflammatory and non-narcotic analgesic drugs are associated with risk of non-Hodgkin's lymphoma (NHL). Methods: A case–control study was conducted among women living in upstate New York. The study involved 376 cases of NHL identified through the New York State Cancer Registry and 463 controls randomly selected from the Medicare beneficiary files and New York State driver's license records. Information regarding use of common medications in the past 20 years and potential confounding variables was obtained by telephone interview. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using an unconditional logistic regression model. Results: There were non-significant increases in risk associated with ever use of cortisone injections and oral cortisone (OR = 1.44 (Cl 0.98–2.11) for injections and 1.21 (CI 0.73–2.00) for oral cortisone, although there was no clear dose–response relationship with either type. On the other hand, the risk of NHL progressively increased with the frequency of use of non-steroidal anti-inflammatory and non-narcotic analgesic drugs (NSAID/NNAD) (p-value for trend 0.008). Women who used any of these medications daily for more than 10 years had an OR of 1.90 (CI 1.01–3.57), compared with those who used it less than once a month on average. The risk associated with long-term use was most pronounced for ibuprofen, intermediate for aspirin, and least for acetaminophen. Conclusions: Because the population-attributable risk associated with NSAID/NNAD use is potentially large, our results need to be verified in further epidemiologic studies.
Tài liệu tham khảo
Filipovich AH, Mathur A, Kamat D, Shapiro RS (1992) Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 52: 5465s-5467s.
Beral V, Peterman T, Berkelman R, Jaffe H (1991) AIDSassociated non-Hodgkin lymphoma. Lancet 337: 805–809.
Rabkin CS, Biggar RJ, Horm JW (1991) Increasing incidence of cancers associated with the human immunodeficiency virus epidemic. Int J Cancer 47: 692–696.
McWhorter WP (1998) Allergy and cancer: a prospective study using NHANES I follow-up data. Cancer 62: 451–455.
Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150: 375–389.
Vineis P, Crosignani P, Sacerdote C, et al. (2000) Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 54: 431–436.
Thomas E, Brewster DH, Black RJ, MacFarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88: 497–502.
Kato I, Tajima K, Suchi T, Aozasa K, Matsuzuka F, Kuma K, Tominaga S (1985) Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. Jpn J Cancer Res 76: 1085–1090.
Mellemkjær L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40: 761–768.
Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317: 180–181.
Kauppi M, Pukkala E, Isomäki H (1997) Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis. Cancer Causes Control 8: 201–204.
Rosenthal AK, McLaughlin JK, Gridley G, Nyre´ n O (1995) Incidence of cancer among patients with systemic sclerosis. Cancer 76: 910–914.
Sibilia J, Liote F, Mariette X (1998) Lymphoproliferative disorders in rheumatoid arthritis patients on low dose methotrexate. Rev Rheum Engl Ed 65: 267–273.
Copie-Bergman C, Niedobitek G, Mangham DC, et al. (1997) Epstein-Barr virus in B-cell lymphomas associated with chronic suppurative inflammation. J Pathol 183: 287–292.
Groves FD, Linet MS, Travis LB, Devesa SS (2000) Cancer Surveillance Series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92: 1240–1251.
London NJ, Farmery SM, Will EJ, Davison AM, Lodge JPA (1995) Risk of neoplasia in renal transplant patients. Lancet 346: 403–406.
Nalesnik MA (1998) Clinical and pathological features of posttransplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 20: 325–342.
Harris NC, Jaffe ES, Stein H, et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392.
Breslow NE, Day NE (1980) Statistical Methods in Cancer Research, Vol. I: The Analysis of Case-Control Studies. IARC Scientific Publications No. 32. Lyon: IARC.
Glass AG, Karnell LH, Menck HR (1997) The National Cancer Data Base Report on non-Hodgkin's lymphoma. Cancer 80: 2311–2320.
Dalton SO, Johansen C, Mellemkjær L, et al. (2000) Antidepressant medications and risk for cancer. Epidemiology 11: 171–176.
Garbe E, LeLorier J, Boivin J-F, Suissa S (1997) Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 277: 722–727.
Doody MM, Linet MS, Glass AG, et al. (1996) Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. Epidemiology 7: 131–139.
Harlow S, Linet M (1989) Agreement between questionnaire data and medical records: the evidence for accuracy of recall. Am J Epidemiol 129: 233–248.
Mitchell AA, Cottler LB, Shapiro S (1986) Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 123: 670–676.
Freidenreich CM (1994) Improving long-term recall in epidemiologic studies. Epidemiology 5: 1–4.
Klungel OH, de Boer A, Paes AHP, Herings RMC, Seidell JC, Bakker A (2000) Influence of question structure on the recall of self-reported drug use. J Clin Epidemiol 53: 273–277.
Lipworth L, Fryzek JP, Fored CM, Blot WJ, McLaighlin JK (2001) Comparison of surrogate with self-respondents regarding medical history and prior medication use. Int J Epidemiol 30: 303–308.
Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52 (Suppl.): 5510s-5515s.
Jick SS, Vasilakis-Scaramozza C, Maier WC (2001) The risk of cataract among users of inhaled steroids. Epidemiology 12: 229–234.
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327.
Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146.
Rumore MM, Aron SM, Hiross EJ (1987) A review of action of aspirin and its potential as an immunomodulating agent. Med Hypotheses 22: 387–400.
IARC (1997) IARC Handbooks of Cancer Prevention, Vol. 1: Non-Steroidal Anti-Inflammatory Drugs. Lyon: IARC.
Goodwin JS (1984) Mechanisms of action of nonsteroidal antiinflammatory agents. Am J Med 77: 57–64.
Conti P, Cifone MG, Alesse E, Ianni G, Angeletti PU (1982) Effects of salicylates on lymphocyte blastogenesis in vitro: associ-Corticosteroid, NSAIDs and NHL 973 ation with other non-steroid anti-inflammatory drugs. Clin Rheumatol 2: 127–132.
Botting R (2000) Paracetamol-inhibitable COX-2. J Physiol Pharmacol 31: 609–618.
Graham NMH, Burrell CJ, Douglas RM, Debelle P, Davies L (1990) Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirusinfected volunteers. J Infect Dis 162: 1277–1282.
Lawrence RC, Helmick CG, Arnett FC, et al. (1999) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41: 778–799.